Therapeutic potential of HIV-1 entry inhibitor peptidomimetics

Nneka P.U. Korie, Kwesi Z. Tandoh, Samuel K. Kwofie, Osbourne Quaye

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Human immunodeficiency virus 1 (HIV-1) infection remains a public health concern globally. Although great strides in the management of HIV-1 have been achieved, current highly active antiretroviral therapy is limited by multidrug resistance, prolonged use-related effects, and inability to purge the HIV-1 latent pool. Even though novel therapeutic options with HIV-1 broadly neutralizing antibodies (bNAbs) are being explored, the scalability of bNAbs is limited by economic cost of production and obligatory requirement for parenteral administration. However, these limitations can be addressed by antibody mimetics/peptidomimetics of HIV-1 bNAbs. In this review we discuss the limitations of HIV-1 bNAbs as HIV-1 entry inhibitors and explore the potential therapeutic use of antibody mimetics/peptidomimetics of HIV-1 entry inhibitors as an alternative for HIV-1 bNAbs. We highlight the reduced cost of production, high specificity, and oral bioavailability of peptidomimetics compared to bNAbs to demonstrate their suitability as candidates for novel HIV-1 therapy and conclude with some perspectives on future research toward HIV-1 novel drug discovery.

Original languageEnglish
Pages (from-to)1060-1068
Number of pages9
JournalExperimental Biology and Medicine
Volume246
Issue number9
DOIs
Publication statusPublished - May 2021

Keywords

  • HIV-1 novel drug discovery
  • Human immunodeficiency virus 1
  • antiretroviral therapy
  • broadly neutralizing antibodies
  • entry inhibitors
  • peptidomimetics

Fingerprint

Dive into the research topics of 'Therapeutic potential of HIV-1 entry inhibitor peptidomimetics'. Together they form a unique fingerprint.

Cite this